APO Research
Talk to an analyst

APO RESEARCH · REPORT

General Medicines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global General Medicines Market Outlook and Growth Opportunities 2026

30 December 2025216 pages

Choose your research edition.

Industry ResearchGeneral Medicines Industry Research Report 2026147 pages · $2,950 USDIndustry Growth & TrendsGlobal General Medicines Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal General Medicines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal General Medicines Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal General Medicines Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global General Medicines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for General Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for General Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for General Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the General Medicines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the General Medicines market include Sun Pharmaceutical, Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer and Jiangsu Hengrui Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global General Medicines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of General Medicines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents General Medicines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the General Medicines market size, projected growth trends, production technologies, key applications, and end-use industries.

General Medicines Segment by Company

Sun Pharmaceutical

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Jiangsu Hengrui Medicine

Bayer

Amgen

AbbVie

AstraZeneca

Zoetis

Vertex Pharmaceuticals

Takeda Pharmaceutical

Seagen

Regeneron Pharmaceuticals

Novo Nordisk

Moderna

Lonza

Horizon Therapeutics

GlaxoSmithKline

Gilead Sciences

Daiichi Sankyō

CVS Health

Chugai Pharmaceutical

Bristol-Myers Squibb

Biogen

Argenx

General Medicines Segment by Type

Over-the-Counter (OTC)

Prescription (Rx)

General Medicines Segment by Application

Antihypertensives

Antibiotics

Antidiabetic Drugs

Antipyretics

Analgesics

Others

General Medicines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global General Medicines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions General Medicines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify General Medicines significant trends, drivers, influence factors in global and regions.

6. To analyze General Medicines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global General Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of General Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of General Medicines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the General Medicines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global General Medicines industry.

Chapter 3: Detailed analysis of General Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of General Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of General Medicines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. General Medicines Industry Trends Table 2. General Medicines Industry Drivers Table 3. General Medicines Industry Opportunities and Challenges Table 4. General Medicines Industry Restraints Table 5. Global General Medicines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global General Medicines Revenue Share by Company (2021-2026) Table 7. Global General Medicines Sales Volume by Company (K Units) & (2021-2026) Table 8. Global General Medicines Sales Volume Share by Company (2021-2026) Table 9. Global General Medicines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global General Medicines Company Ranking, (2024-2026) & (USD Million) Table 11. Global General Medicines Key Company Manufacturing Base & Headquarters Table 12. Global General Medicines Company, Product Type & Application Table 13. Global General Medicines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global General Medicines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Over-the-Counter (OTC) Table 18. Significant Companies of Prescription (Rx) Table 19. Global General Medicines Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global General Medicines Sales Volume by Type (2021-2026) & (K Units) Table 21. Global General Medicines Sales Volume by Type (2027-2032) & (K Units) Table 22. Global General Medicines Sales Volume Share by Type (2021-2026) Table 23. Global General Medicines Sales Volume Share by Type (2027-2032) Table 24. Global General Medicines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global General Medicines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global General Medicines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global General Medicines Sales Value Share by Type (2021-2026) Table 28. Global General Medicines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Antihypertensives Table 30. Significant Companies of Antibiotics Table 31. Significant Companies of Antidiabetic Drugs Table 32. Significant Companies of Antipyretics Table 33. Significant Companies of Analgesics Table 34. Significant Companies of Others Table 35. Global General Medicines Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global General Medicines Sales Volume by Application (2021-2026) & (K Units) Table 37. Global General Medicines Sales Volume by Application (2027-2032) & (K Units) Table 38. Global General Medicines Sales Volume Share by Application (2021-2026) Table 39. Global General Medicines Sales Volume Share by Application (2027-2032) Table 40. Global General Medicines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global General Medicines Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global General Medicines Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global General Medicines Sales Value Share by Application (2021-2026) Table 44. Global General Medicines Sales Value Share by Application (2027-2032) Table 45. Global General Medicines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global General Medicines Sales by Region (2021-2026) & (K Units) Table 47. Global General Medicines Sales Market Share by Region (2021-2026) Table 48. Global General Medicines Sales by Region (2027-2032) & (K Units) Table 49. Global General Medicines Sales Market Share by Region (2027-2032) Table 50. Global General Medicines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global General Medicines Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global General Medicines Sales Value Share by Region (2021-2026) Table 53. Global General Medicines Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global General Medicines Sales Value Share by Region (2027-2032) Table 55. Global General Medicines Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global General Medicines Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global General Medicines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global General Medicines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global General Medicines Sales by Country (2021-2026) & (K Units) Table 60. Global General Medicines Sales Market Share by Country (2021-2026) Table 61. Global General Medicines Sales by Country (2027-2032) & (K Units) Table 62. Global General Medicines Sales Market Share by Country (2027-2032) Table 63. Global General Medicines Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global General Medicines Sales Value Market Share by Country (2021-2026) Table 65. Global General Medicines Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global General Medicines Sales Value Market Share by Country (2027-2032) Table 67. Sun Pharmaceutical Company Information Table 68. Sun Pharmaceutical Business Overview Table 69. Sun Pharmaceutical General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Sun Pharmaceutical General Medicines Product Portfolio Table 71. Sun Pharmaceutical Recent Development Table 72. Sanofi Company Information Table 73. Sanofi Business Overview Table 74. Sanofi General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Sanofi General Medicines Product Portfolio Table 76. Sanofi Recent Development Table 77. Johnson & Johnson Company Information Table 78. Johnson & Johnson Business Overview Table 79. Johnson & Johnson General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Johnson & Johnson General Medicines Product Portfolio Table 81. Johnson & Johnson Recent Development Table 82. Novartis Company Information Table 83. Novartis Business Overview Table 84. Novartis General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Novartis General Medicines Product Portfolio Table 86. Novartis Recent Development Table 87. Merck Company Information Table 88. Merck Business Overview Table 89. Merck General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Merck General Medicines Product Portfolio Table 91. Merck Recent Development Table 92. Roche Company Information Table 93. Roche Business Overview Table 94. Roche General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Roche General Medicines Product Portfolio Table 96. Roche Recent Development Table 97. Eli Lilly Company Information Table 98. Eli Lilly Business Overview Table 99. Eli Lilly General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Eli Lilly General Medicines Product Portfolio Table 101. Eli Lilly Recent Development Table 102. Pfizer Company Information Table 103. Pfizer Business Overview Table 104. Pfizer General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Pfizer General Medicines Product Portfolio Table 106. Pfizer Recent Development Table 107. Jiangsu Hengrui Medicine Company Information Table 108. Jiangsu Hengrui Medicine Business Overview Table 109. Jiangsu Hengrui Medicine General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Jiangsu Hengrui Medicine General Medicines Product Portfolio Table 111. Jiangsu Hengrui Medicine Recent Development Table 112. Bayer Company Information Table 113. Bayer Business Overview Table 114. Bayer General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Bayer General Medicines Product Portfolio Table 116. Bayer Recent Development Table 117. Amgen Company Information Table 118. Amgen Business Overview Table 119. Amgen General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Amgen General Medicines Product Portfolio Table 121. Amgen Recent Development Table 122. AbbVie Company Information Table 123. AbbVie Business Overview Table 124. AbbVie General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. AbbVie General Medicines Product Portfolio Table 126. AbbVie Recent Development Table 127. AstraZeneca Company Information Table 128. AstraZeneca Business Overview Table 129. AstraZeneca General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. AstraZeneca General Medicines Product Portfolio Table 131. AstraZeneca Recent Development Table 132. Zoetis Company Information Table 133. Zoetis Business Overview Table 134. Zoetis General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Zoetis General Medicines Product Portfolio Table 136. Zoetis Recent Development Table 137. Vertex Pharmaceuticals Company Information Table 138. Vertex Pharmaceuticals Business Overview Table 139. Vertex Pharmaceuticals General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Vertex Pharmaceuticals General Medicines Product Portfolio Table 141. Vertex Pharmaceuticals Recent Development Table 142. Takeda Pharmaceutical Company Information Table 143. Takeda Pharmaceutical Business Overview Table 144. Takeda Pharmaceutical General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Takeda Pharmaceutical General Medicines Product Portfolio Table 146. Takeda Pharmaceutical Recent Development Table 147. Seagen Company Information Table 148. Seagen Business Overview Table 149. Seagen General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Seagen General Medicines Product Portfolio Table 151. Seagen Recent Development Table 152. Regeneron Pharmaceuticals Company Information Table 153. Regeneron Pharmaceuticals Business Overview Table 154. Regeneron Pharmaceuticals General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Regeneron Pharmaceuticals General Medicines Product Portfolio Table 156. Regeneron Pharmaceuticals Recent Development Table 157. Novo Nordisk Company Information Table 158. Novo Nordisk Business Overview Table 159. Novo Nordisk General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Novo Nordisk General Medicines Product Portfolio Table 161. Novo Nordisk Recent Development Table 162. Moderna Company Information Table 163. Moderna Business Overview Table 164. Moderna General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Moderna General Medicines Product Portfolio Table 166. Moderna Recent Development Table 167. Lonza Company Information Table 168. Lonza Business Overview Table 169. Lonza General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Lonza General Medicines Product Portfolio Table 171. Lonza Recent Development Table 172. Horizon Therapeutics Company Information Table 173. Horizon Therapeutics Business Overview Table 174. Horizon Therapeutics General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. Horizon Therapeutics General Medicines Product Portfolio Table 176. Horizon Therapeutics Recent Development Table 177. GlaxoSmithKline Company Information Table 178. GlaxoSmithKline Business Overview Table 179. GlaxoSmithKline General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 180. GlaxoSmithKline General Medicines Product Portfolio Table 181. GlaxoSmithKline Recent Development Table 182. Gilead Sciences Company Information Table 183. Gilead Sciences Business Overview Table 184. Gilead Sciences General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 185. Gilead Sciences General Medicines Product Portfolio Table 186. Gilead Sciences Recent Development Table 187. Daiichi Sankyō Company Information Table 188. Daiichi Sankyō Business Overview Table 189. Daiichi Sankyō General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 190. Daiichi Sankyō General Medicines Product Portfolio Table 191. Daiichi Sankyō Recent Development Table 192. CVS Health Company Information Table 193. CVS Health Business Overview Table 194. CVS Health General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 195. CVS Health General Medicines Product Portfolio Table 196. CVS Health Recent Development Table 197. Chugai Pharmaceutical Company Information Table 198. Chugai Pharmaceutical Business Overview Table 199. Chugai Pharmaceutical General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 200. Chugai Pharmaceutical General Medicines Product Portfolio Table 201. Chugai Pharmaceutical Recent Development Table 202. Bristol-Myers Squibb Company Information Table 203. Bristol-Myers Squibb Business Overview Table 204. Bristol-Myers Squibb General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 205. Bristol-Myers Squibb General Medicines Product Portfolio Table 206. Bristol-Myers Squibb Recent Development Table 207. Biogen Company Information Table 208. Biogen Business Overview Table 209. Biogen General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 210. Biogen General Medicines Product Portfolio Table 211. Biogen Recent Development Table 212. Argenx Company Information Table 213. Argenx Business Overview Table 214. Argenx General Medicines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 215. Argenx General Medicines Product Portfolio Table 216. Argenx Recent Development Table 217. Key Raw Materials Table 218. Raw Materials Key Suppliers Table 219. General Medicines Distributors List Table 220. General Medicines Customers List Table 221. Research Programs/Design for This Report Table 222. Authors List of This Report Table 223. Secondary Sources Table 224. Primary Sources List of Figures Figure 1. General Medicines Product Image Figure 2. Global General Medicines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global General Medicines Sales Value (2021-2032) & (US$ Million) Figure 4. Global General Medicines Sales (2021-2032) & (K Units) Figure 5. Global General Medicines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global General Medicines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Over-the-Counter (OTC) Image Figure 10. Prescription (Rx) Image Figure 11. Global General Medicines Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global General Medicines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global General Medicines Sales Volume Share by Type (2021-2032) Figure 14. Global General Medicines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global General Medicines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global General Medicines Sales Value Share by Type (2021-2032) Figure 17. Antihypertensives Image Figure 18. Antibiotics Image Figure 19. Antidiabetic Drugs Image Figure 20. Antipyretics Image Figure 21. Analgesics Image Figure 22. Others Image Figure 23. Global General Medicines Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global General Medicines Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global General Medicines Sales Volume Share by Application (2021-2032) Figure 26. Global General Medicines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global General Medicines Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global General Medicines Sales Value Share by Application (2021-2032) Figure 29. Global General Medicines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global General Medicines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global General Medicines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global General Medicines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America General Medicines Sales Value (2021-2032) & (US$ Million) Figure 34. North America General Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe General Medicines Sales Value (2021-2032) & (US$ Million) Figure 36. Europe General Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific General Medicines Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific General Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America General Medicines Sales Value (2021-2032) & (US$ Million) Figure 40. South America General Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa General Medicines Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa General Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt General Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt General Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt General Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. General Medicines Value Chain Figure 128. Manufacturing Cost Structure Figure 129. General Medicines Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Over-the-Counter (OTC)
  • Prescription (Rx)
Applications
  • Antihypertensives
  • Antibiotics
  • Antidiabetic Drugs
  • Antipyretics
  • Analgesics
  • Others
Companies covered
  • Sun Pharmaceutical
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Jiangsu Hengrui Medicine
  • Bayer
  • Amgen
  • AbbVie
  • AstraZeneca
  • Zoetis
  • Vertex Pharmaceuticals
  • Takeda Pharmaceutical
  • Seagen
  • Regeneron Pharmaceuticals
  • Novo Nordisk
  • Moderna
  • Lonza
  • Horizon Therapeutics
  • GlaxoSmithKline
  • Gilead Sciences
  • Daiichi Sankyō
  • CVS Health
  • Chugai Pharmaceutical
  • Bristol-Myers Squibb
  • Biogen
  • Argenx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global General Medicines Sales Value (2021-2032)
  4. 1.2.2 Global General Medicines Sales Volume (2021-2032)
  5. 1.2.3 Global General Medicines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 General Medicines Market Dynamics
  1. 2.1 General Medicines Industry Trends
  2. 2.2 General Medicines Industry Drivers
  3. 2.3 General Medicines Industry Opportunities and Challenges
  4. 2.4 General Medicines Industry Restraints
3 General Medicines Market by Company
  1. 3.1 Global General Medicines Company Revenue Ranking in 2025
  2. 3.2 Global General Medicines Revenue by Company (2021-2026)
  3. 3.3 Global General Medicines Sales Volume by Company (2021-2026)
  4. 3.4 Global General Medicines Average Price by Company (2021-2026)
  5. 3.5 Global General Medicines Company Ranking (2024-2026)
  6. 3.6 Global General Medicines Company Manufacturing Base and Headquarters
  7. 3.7 Global General Medicines Company Product Type and Application
  8. 3.8 Global General Medicines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global General Medicines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 General Medicines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 General Medicines Market by Type
  1. 4.1 General Medicines Type Introduction
  2. 4.1.1 Over-the-Counter (OTC)
  3. 4.1.2 Prescription (Rx)
  4. 4.2 Global General Medicines Sales Volume by Type
  5. 4.2.1 Global General Medicines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global General Medicines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global General Medicines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global General Medicines Sales Value by Type
  9. 4.3.1 Global General Medicines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global General Medicines Sales Value by Type (2021-2032)
  11. 4.3.3 Global General Medicines Sales Value Share by Type (2021-2032)
5 General Medicines Market by Application
  1. 5.1 General Medicines Application Introduction
  2. 5.1.1 Antihypertensives
  3. 5.1.2 Antibiotics
  4. 5.1.3 Antidiabetic Drugs
  5. 5.1.4 Antipyretics
  6. 5.1.5 Analgesics
  7. 5.1.6 Others
  8. 5.2 Global General Medicines Sales Volume by Application
  9. 5.2.1 Global General Medicines Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global General Medicines Sales Volume by Application (2021-2032)
  11. 5.2.3 Global General Medicines Sales Volume Share by Application (2021-2032)
  12. 5.3 Global General Medicines Sales Value by Application
  13. 5.3.1 Global General Medicines Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global General Medicines Sales Value by Application (2021-2032)
  15. 5.3.3 Global General Medicines Sales Value Share by Application (2021-2032)
6 General Medicines Regional Sales and Value Analysis
  1. 6.1 Global General Medicines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global General Medicines Sales by Region (2021-2032)
  3. 6.2.1 Global General Medicines Sales by Region: 2021-2026
  4. 6.2.2 Global General Medicines Sales by Region (2027-2032)
  5. 6.3 Global General Medicines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global General Medicines Sales Value by Region (2021-2032)
  7. 6.4.1 Global General Medicines Sales Value by Region: 2021-2026
  8. 6.4.2 Global General Medicines Sales Value by Region (2027-2032)
  9. 6.5 Global General Medicines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America General Medicines Sales Value (2021-2032)
  12. 6.6.2 North America General Medicines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe General Medicines Sales Value (2021-2032)
  15. 6.7.2 Europe General Medicines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific General Medicines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific General Medicines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America General Medicines Sales Value (2021-2032)
  21. 6.9.2 South America General Medicines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa General Medicines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa General Medicines Sales Value Share by Country, 2025 VS 2032
7 General Medicines Country-level Sales and Value Analysis
  1. 7.1 Global General Medicines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global General Medicines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global General Medicines Sales by Country (2021-2032)
  4. 7.3.1 Global General Medicines Sales by Country (2021-2026)
  5. 7.3.2 Global General Medicines Sales by Country (2027-2032)
  6. 7.4 Global General Medicines Sales Value by Country (2021-2032)
  7. 7.4.1 Global General Medicines Sales Value by Country (2021-2026)
  8. 7.4.2 Global General Medicines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA General Medicines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA General Medicines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA General Medicines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada General Medicines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada General Medicines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada General Medicines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico General Medicines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico General Medicines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico General Medicines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany General Medicines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany General Medicines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany General Medicines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France General Medicines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France General Medicines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France General Medicines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. General Medicines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. General Medicines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. General Medicines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy General Medicines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy General Medicines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy General Medicines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain General Medicines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain General Medicines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain General Medicines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia General Medicines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia General Medicines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia General Medicines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands General Medicines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands General Medicines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands General Medicines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries General Medicines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries General Medicines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries General Medicines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China General Medicines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China General Medicines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China General Medicines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan General Medicines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan General Medicines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan General Medicines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea General Medicines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea General Medicines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea General Medicines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India General Medicines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India General Medicines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India General Medicines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia General Medicines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia General Medicines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia General Medicines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia General Medicines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia General Medicines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia General Medicines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil General Medicines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil General Medicines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil General Medicines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina General Medicines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina General Medicines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina General Medicines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile General Medicines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile General Medicines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile General Medicines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia General Medicines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia General Medicines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia General Medicines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru General Medicines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru General Medicines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru General Medicines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia General Medicines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia General Medicines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia General Medicines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel General Medicines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel General Medicines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel General Medicines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE General Medicines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE General Medicines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE General Medicines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey General Medicines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey General Medicines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey General Medicines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran General Medicines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran General Medicines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran General Medicines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt General Medicines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt General Medicines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt General Medicines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sun Pharmaceutical
  2. 8.1.1 Sun Pharmaceutical Company Information
  3. 8.1.2 Sun Pharmaceutical Business Overview
  4. 8.1.3 Sun Pharmaceutical General Medicines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sun Pharmaceutical General Medicines Product Portfolio
  6. 8.1.5 Sun Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi General Medicines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi General Medicines Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson General Medicines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson General Medicines Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis General Medicines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis General Medicines Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck General Medicines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck General Medicines Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche General Medicines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Roche General Medicines Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly General Medicines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly General Medicines Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer General Medicines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer General Medicines Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Jiangsu Hengrui Medicine
  50. 8.9.1 Jiangsu Hengrui Medicine Company Information
  51. 8.9.2 Jiangsu Hengrui Medicine Business Overview
  52. 8.9.3 Jiangsu Hengrui Medicine General Medicines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Hengrui Medicine General Medicines Product Portfolio
  54. 8.9.5 Jiangsu Hengrui Medicine Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer General Medicines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bayer General Medicines Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 Amgen
  62. 8.11.1 Amgen Company Information
  63. 8.11.2 Amgen Business Overview
  64. 8.11.3 Amgen General Medicines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Amgen General Medicines Product Portfolio
  66. 8.11.5 Amgen Recent Developments
  67. 8.12 AbbVie
  68. 8.12.1 AbbVie Company Information
  69. 8.12.2 AbbVie Business Overview
  70. 8.12.3 AbbVie General Medicines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 AbbVie General Medicines Product Portfolio
  72. 8.12.5 AbbVie Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca General Medicines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca General Medicines Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
  79. 8.14 Zoetis
  80. 8.14.1 Zoetis Company Information
  81. 8.14.2 Zoetis Business Overview
  82. 8.14.3 Zoetis General Medicines Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Zoetis General Medicines Product Portfolio
  84. 8.14.5 Zoetis Recent Developments
  85. 8.15 Vertex Pharmaceuticals
  86. 8.15.1 Vertex Pharmaceuticals Company Information
  87. 8.15.2 Vertex Pharmaceuticals Business Overview
  88. 8.15.3 Vertex Pharmaceuticals General Medicines Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Vertex Pharmaceuticals General Medicines Product Portfolio
  90. 8.15.5 Vertex Pharmaceuticals Recent Developments
  91. 8.16 Takeda Pharmaceutical
  92. 8.16.1 Takeda Pharmaceutical Company Information
  93. 8.16.2 Takeda Pharmaceutical Business Overview
  94. 8.16.3 Takeda Pharmaceutical General Medicines Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Takeda Pharmaceutical General Medicines Product Portfolio
  96. 8.16.5 Takeda Pharmaceutical Recent Developments
  97. 8.17 Seagen
  98. 8.17.1 Seagen Company Information
  99. 8.17.2 Seagen Business Overview
  100. 8.17.3 Seagen General Medicines Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Seagen General Medicines Product Portfolio
  102. 8.17.5 Seagen Recent Developments
  103. 8.18 Regeneron Pharmaceuticals
  104. 8.18.1 Regeneron Pharmaceuticals Company Information
  105. 8.18.2 Regeneron Pharmaceuticals Business Overview
  106. 8.18.3 Regeneron Pharmaceuticals General Medicines Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Regeneron Pharmaceuticals General Medicines Product Portfolio
  108. 8.18.5 Regeneron Pharmaceuticals Recent Developments
  109. 8.19 Novo Nordisk
  110. 8.19.1 Novo Nordisk Company Information
  111. 8.19.2 Novo Nordisk Business Overview
  112. 8.19.3 Novo Nordisk General Medicines Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Novo Nordisk General Medicines Product Portfolio
  114. 8.19.5 Novo Nordisk Recent Developments
  115. 8.20 Moderna
  116. 8.20.1 Moderna Company Information
  117. 8.20.2 Moderna Business Overview
  118. 8.20.3 Moderna General Medicines Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Moderna General Medicines Product Portfolio
  120. 8.20.5 Moderna Recent Developments
  121. 8.21 Lonza
  122. 8.21.1 Lonza Company Information
  123. 8.21.2 Lonza Business Overview
  124. 8.21.3 Lonza General Medicines Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Lonza General Medicines Product Portfolio
  126. 8.21.5 Lonza Recent Developments
  127. 8.22 Horizon Therapeutics
  128. 8.22.1 Horizon Therapeutics Company Information
  129. 8.22.2 Horizon Therapeutics Business Overview
  130. 8.22.3 Horizon Therapeutics General Medicines Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Horizon Therapeutics General Medicines Product Portfolio
  132. 8.22.5 Horizon Therapeutics Recent Developments
  133. 8.23 GlaxoSmithKline
  134. 8.23.1 GlaxoSmithKline Company Information
  135. 8.23.2 GlaxoSmithKline Business Overview
  136. 8.23.3 GlaxoSmithKline General Medicines Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 GlaxoSmithKline General Medicines Product Portfolio
  138. 8.23.5 GlaxoSmithKline Recent Developments
  139. 8.24 Gilead Sciences
  140. 8.24.1 Gilead Sciences Company Information
  141. 8.24.2 Gilead Sciences Business Overview
  142. 8.24.3 Gilead Sciences General Medicines Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Gilead Sciences General Medicines Product Portfolio
  144. 8.24.5 Gilead Sciences Recent Developments
  145. 8.25 Daiichi Sankyō
  146. 8.25.1 Daiichi Sankyō Company Information
  147. 8.25.2 Daiichi Sankyō Business Overview
  148. 8.25.3 Daiichi Sankyō General Medicines Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Daiichi Sankyō General Medicines Product Portfolio
  150. 8.25.5 Daiichi Sankyō Recent Developments
  151. 8.26 CVS Health
  152. 8.26.1 CVS Health Company Information
  153. 8.26.2 CVS Health Business Overview
  154. 8.26.3 CVS Health General Medicines Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 CVS Health General Medicines Product Portfolio
  156. 8.26.5 CVS Health Recent Developments
  157. 8.27 Chugai Pharmaceutical
  158. 8.27.1 Chugai Pharmaceutical Company Information
  159. 8.27.2 Chugai Pharmaceutical Business Overview
  160. 8.27.3 Chugai Pharmaceutical General Medicines Sales, Value and Gross Margin (2021-2026)
  161. 8.27.4 Chugai Pharmaceutical General Medicines Product Portfolio
  162. 8.27.5 Chugai Pharmaceutical Recent Developments
  163. 8.28 Bristol-Myers Squibb
  164. 8.28.1 Bristol-Myers Squibb Company Information
  165. 8.28.2 Bristol-Myers Squibb Business Overview
  166. 8.28.3 Bristol-Myers Squibb General Medicines Sales, Value and Gross Margin (2021-2026)
  167. 8.28.4 Bristol-Myers Squibb General Medicines Product Portfolio
  168. 8.28.5 Bristol-Myers Squibb Recent Developments
  169. 8.29 Biogen
  170. 8.29.1 Biogen Company Information
  171. 8.29.2 Biogen Business Overview
  172. 8.29.3 Biogen General Medicines Sales, Value and Gross Margin (2021-2026)
  173. 8.29.4 Biogen General Medicines Product Portfolio
  174. 8.29.5 Biogen Recent Developments
  175. 8.30 Argenx
  176. 8.30.1 Argenx Company Information
  177. 8.30.2 Argenx Business Overview
  178. 8.30.3 Argenx General Medicines Sales, Value and Gross Margin (2021-2026)
  179. 8.30.4 Argenx General Medicines Product Portfolio
  180. 8.30.5 Argenx Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 General Medicines Value Chain Analysis
  2. 9.1.1 General Medicines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 General Medicines Sales Mode & Process
  6. 9.2 General Medicines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 General Medicines Distributors
  9. 9.2.3 General Medicines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst